Investors

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Safety and efficacy results of the combination of DPX-Survivac, pembrolizumab and intermittent low dose cyclophosphamide (CPA) in subjects with advanced and metastatic solid tumours (preliminary results)PDF

Sep 30, 2019

Supporting Materials